Almeida highlighted the increasing prevalence of diabetic macular edema and the importance of developing safe, well-tolerated treatments.

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

Rezolute has done well to continue to advance its lead drug from its pipeline, ersodetug. Click here to see why RZLT stock is ...

Researchers have discovered in an ongoing phase IIb trial that a single intravitreal injection of UBX1325 (foselutoclax), a ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

4D Molecular Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its product 4D-150 for treating diabetic macular edema (DME). This ...

In July 2014, the U.S. FDA approved EYLEA (aflibercept) Injection for treating diabetic macular edema (DME). Ranibizumab (Genentech) – Marketed as LUCENTIS, ranibizumab is a monoclonal antibody ...

The findings cover its use in wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR), offering insights into real-world applications that ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...